论文部分内容阅读
目的:探讨腹部透热全身热疗系统在晚期复治性原发性肝癌、胃肠道癌及间质肿瘤恶性腹水腹腔化疗治疗中的辅助及增效治疗作用价值及意义。方法:试验组(18例)抽放恶性腹水后腹腔内灌注DDP+5-FU主药物后即刻行高功率微波腹部透热全身热疗,恒温期温度41~42℃,维持>60 min。对照组(24例)仅行腹腔灌注化疗,用药方法同试验组。结果:42例复治恶性腹水总缓解率57.1%(24/42),其中试验组77.8%(14/18),对照组41.7%(10/24),前者有效率明显高于后者,差异有统计学意义,P<0.05。试验组及对照组患者中位生存时间分别为30和25周。2组不同治疗方法的毒副反应发生率及程度差异无统计学意义,P>0.05。结论:以腹腔灌注化疗联合经腹透热全身热疗治疗晚期肿瘤恶性腹水较常规单纯腹腔化疗疗效好,且毒副反应少,并有一定程度延长患者生存期作用,有临床实际应用价值。
Objective: To investigate the value and significance of abdominal diathermy whole body hyperthermia system in the adjuvant and synergistic treatment of advanced retroperitoneal hepatocellular carcinoma, gastrointestinal cancer and interstitial malignant ascites peritoneal chemotherapy. Methods: The experimental group (n = 18) was treated with intraperitoneal perfusion of DDP + 5-FU after intraperitoneal drainage of malignant ascites. The whole body was treated with high-power microwave abdominal diathermy. The temperature was 41-42 ℃ and maintained for> 60 min. Control group (24 cases) only intraperitoneal perfusion chemotherapy, medication method with the experimental group. Results: The total remission rate of malignant ascites in 42 cases was 57.1% (24/42), of which 77.8% (14/18) in the trial group and 41.7% (10/24) in the control group, the former was significantly higher than the latter There was statistical significance, P <0.05. The median survival time in trial and control groups was 30 and 25 weeks, respectively. There was no significant difference in the incidence and degree of toxic side effects between the two groups in different treatment methods (P> 0.05). Conclusion: Peritoneal perfusion chemotherapy combined with transvenous hyperthermic generalized hyperthermia in the treatment of advanced malignant ascites possesses better curative effect than conventional simple peritoneal chemotherapy with less toxic side effects and prolongation of the survival of patients with certain degree of clinical practical value.